Cargando…

Dimebon Does Not Ameliorate Pathological Changes Caused by Expression of Truncated (1–120) Human Alpha-Synuclein in Dopaminergic Neurons of Transgenic Mice

BACKGROUND: Recent clinical studies have demonstrated that dimebon, a drug originally designed and used as a non-selective antihistamine, ameliorates symptoms and delays progress of mild to moderate forms of Alzheimer's and Huntington's diseases. Although the mechanism of dimebon action on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shelkovnikova, Tatyana A., Ustyugov, Alexey A., Millership, Steven, Peters, Owen, Anichtchik, Oleg, Spillantini, Maria Grazia, Buchman, Vladimir L., Bachurin, Sergey O., Ninkina, Natalia N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2011
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186720/ https://www.ncbi.nlm.nih.gov/pubmed/21576917 http://dx.doi.org/10.1159/000324989

Ejemplares similares

Dimebon Slows Progression of Proteinopathy in γ-Synuclein Transgenic Mice
por: Bachurin, Sergey O., et al.
Publicado: (2011)

A bioisostere of Dimebon/Latrepirdine delays the onset and slows the progression of pathology in FUS transgenic mice
por: Chaprov, Kirill, et al.
Publicado: (2021)

Selective pattern of motor system damage in gamma-synuclein transgenic mice mirrors the respective pathology in amyotrophic lateral sclerosis
por: Peters, Owen M., et al.
Publicado: (2012)

A novel resource for studying function and dysfunction of α-synuclein: mouse lines for modulation of endogenous Snca gene expression
por: Ninkina, Natalia, et al.
Publicado: (2015)

β-synuclein potentiates synaptic vesicle dopamine uptake and rescues dopaminergic neurons from MPTP-induced death in the absence of other synucleins
por: Ninkina, Natalia, et al.
Publicado: (2021)

Gamma-synuclein pathology in amyotrophic lateral sclerosis
por: Peters, Owen M, et al.
Publicado: (2015)

γ-synuclein is a novel player in the control of body lipid metabolism
por: Millership, Steven, et al.
Publicado: (2013)

Combinational losses of synucleins reveal their differential requirements for compensating age-dependent alterations in motor behavior and dopamine metabolism
por: Connor-Robson, Natalie, et al.
Publicado: (2016)

Dimebon disappointment
por: Jones, Roy W
Publicado: (2010)

Modulation of α-synuclein expression in transgenic animals for modelling synucleinopathies — is the juice worth the squeeze?
por: Buchman, Vladimir L., et al.
Publicado: (2008)

Fused in Sarcoma (FUS) Protein Lacking Nuclear Localization Signal (NLS) and Major RNA Binding Motifs Triggers Proteinopathy and Severe Motor Phenotype in Transgenic Mice
por: Shelkovnikova, Tatyana A., et al.
Publicado: (2013)

CSPα reduces aggregates and rescues striatal dopamine release in α-synuclein transgenic mice
por: Caló, Laura, et al.
Publicado: (2021)

Lipid Classes and Fatty Acid Patterns are Altered in the Brain of γ-Synuclein Null Mutant Mice
por: Guschina, Irina, et al.
Publicado: (2010)

Absence of α-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice()
por: Al-Wandi, Abdelmojib, et al.
Publicado: (2010)

Frameshift peptides alter the properties of truncated FUS proteins in ALS-FUS
por: An, Haiyan, et al.
Publicado: (2020)

Gamma-Carbolines Derivatives As Promising Agents for the Development of Pathogenic Therapy for Proteinopathy
por: Skvortsova, V. I., et al.
Publicado: (2018)

Evaluation of Dimebon in cellular model of Huntington's disease
por: Wu, Jun, et al.
Publicado: (2008)

Compromised paraspeckle formation as a pathogenic factor in FUSopathies
por: Shelkovnikova, Tatyana A., et al.
Publicado: (2014)

Multistep process of FUS aggregation in the cell cytoplasm involves RNA-dependent and RNA-independent mechanisms
por: Shelkovnikova, Tatyana A., et al.
Publicado: (2014)

Alterations in the nigrostriatal system following conditional inactivation of α-synuclein in neurons of adult and aging mice
por: Ninkina, Natalia, et al.
Publicado: (2020)

Contrasting Effects of α-Synuclein and γ-Synuclein on the Phenotype of Cysteine String Protein α (CSPα) Null Mutant Mice Suggest Distinct Function of these Proteins in Neuronal Synapses
por: Ninkina, Natalia, et al.
Publicado: (2012)

γ-Synucleinopathy: neurodegeneration associated with overexpression of the mouse protein
por: Ninkina, Natalia, et al.
Publicado: (2009)

Synuclein Proteins in MPTP-Induced Death of Substantia Nigra Pars Compacta Dopaminergic Neurons
por: Goloborshcheva, Valeria V., et al.
Publicado: (2022)

Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease
por: Wang, Jun, et al.
Publicado: (2011)

Triple-Knockout, Synuclein-Free Mice Display Compromised Lipid Pattern
por: Guschina, Irina A., et al.
Publicado: (2021)

TDP-43 Potentiates Alpha-synuclein Toxicity to Dopaminergic Neurons in Transgenic Mice
por: Tian, Tian, et al.
Publicado: (2011)

Generation of mouse lines with conditionally or constitutively inactivated Snca gene and Rosa26-stop-lacZ reporter located in cis on the mouse chromosome 6
por: Roman, Andrei Yu., et al.
Publicado: (2016)

Carboxyl truncation of α-synuclein occurs early and is influenced by human APOE genotype in transgenic mouse models of α-synuclein pathogenesis
por: Lloyd, Grace M., et al.
Publicado: (2023)

Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model
por: Wegrzynowicz, Michal, et al.
Publicado: (2019)

Synuclein Deficiency Results in Age-Related Respiratory and Cardiovascular Dysfunctions in Mice
por: Hosford, Patrick S., et al.
Publicado: (2020)

No apparent transmission of transgenic α–synuclein into nigrostriatal dopaminergic neurons in multiple mouse models
por: Sastry, Namratha, et al.
Publicado: (2015)

Differences in bioavailability and cognitive-enhancing activity exerted by different crystal polymorphs of latrepirdine (Dimebon(®))
por: Gorin, Boris I., et al.
Publicado: (2023)

Conditional transgenic mice expressing C-terminally truncated human α-synuclein (αSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons
por: Daher, João Paulo L, et al.
Publicado: (2009)

Neurodegeneration and the ordered assembly of α-synuclein
por: Spillantini, Maria Grazia, et al.
Publicado: (2017)

Mitochondrial Pharmacology of Dimebon (Latrepirdine) Calls for a New Look at its Possible Therapeutic Potential in Alzheimer’s Disease
por: Eckert, Schamim H, et al.
Publicado: (2018)

Long non-coding RNA Neat1 regulates adaptive behavioural response to stress in mice
por: Kukharsky, Michail S., et al.
Publicado: (2020)

Modulation of p-eIF2α cellular levels and stress granule assembly/disassembly by trehalose
por: Dimasi, Pasquale, et al.
Publicado: (2017)

Acute dosing of latrepirdine (Dimebon™), a possible Alzheimer therapeutic, elevates extracellular amyloid-β levels in vitro and in vivo
por: Steele, John W, et al.
Publicado: (2009)

Reduced complement of dopaminergic neurons in the substantia nigra pars compacta of mice with a constitutive “low footprint” genetic knockout of alpha-synuclein
por: Goloborshcheva, Valeria V., et al.
Publicado: (2020)

Editorial of the Special Issue: Recent Advances in Understanding of the Role of Synuclein Family Members in Health and Disease
por: Ninkina, Natalia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9c8kt2c7q0gcf01d76vtt7s4ut